Roopa Industries Ltd

Roopa Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 07 July 2025. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s performance and outlook.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a fresh 52-week low of Rs 41.34, marking a significant decline amid a three-day losing streak that has seen the stock shed nearly 11% of its value. This downturn contrasts sharply with broader market trends and highlights ongoing pressures on the company’s share price.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs 41.34, marking a significant decline amid broader market weakness. The stock has experienced a notable downward trajectory over recent sessions, reflecting ongoing pressures within the company’s financial and market performance.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs 41.34, marking a significant decline amid broader market weakness and sector underperformance.

Roopa Industries has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. The pharmaceutical and biotechnology company’s recent assessment highlights a combination of subdued fundamental strength and bearish market signals, contributing to a cautious stance among investors.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.42, reflecting a significant decline amid a day marked by high volatility and underperformance relative to its sector peers.

Roopa Industries, a player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.43 today, marking a significant price level amid a day of high volatility and mixed intraday movements.

Roopa Industries, a microcap in the Pharmaceuticals & Biotechnology sector, reported a challenging financial quarter ending September 2025, with declines in key metrics such as operating cash flow and return on capital employed. Despite significant long-term growth, recent performance issues underscore the need for operational improvements.

Roopa Industries, a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low of Rs. 45.11 amid ongoing market challenges. The stock has underperformed its sector and shows a significant decline over the past year, reflecting weak financial metrics and a persistent downward trend.

Roopa Industries, a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low of Rs. 45.11, following consecutive losses. The stock is trading below key moving averages and has seen a significant decline over the past year, indicating ongoing challenges for the company.

Roopa Industries has hit a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed its sector and is trading below key moving averages. Despite a profit increase, its financial metrics indicate weak long-term strength, with a low ROCE and high Debt to EBITDA ratio.

Roopa Industries, a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, reflecting a significant decline over the past year. The company is trading below key moving averages and shows weak financial metrics, indicating challenges in its long-term performance and debt management.

Roopa Industries, a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low, reflecting a significant decline in stock performance. The company has underperformed its sector and shows weak long-term fundamentals, including a low Return on Capital Employed and a high Debt to EBITDA ratio.

Roopa Industries, a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low, reflecting a significant decline in stock performance. The company has underperformed its sector and faces challenges with low Return on Capital Employed and a high Debt to EBITDA ratio, despite a profit increase.